Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Confluent Surgical Inc.

This article was originally published in Start Up

Executive Summary

Amar Sawhney has worked with biomaterials several times in his career, as a founder of Focal Inc. and a co-inventor of the technology used by Neocrin Co. and Infimed Inc. Nevertheless, he wants it known that his latest company, Confluent Surgical, is not focusing on biomaterials, but rather on the prevention of surgical adhesions.

You may also be interested in...



I-Therapeutix Inc.

I-Therapeutix is developing a hydrogel-based surgical sealant for ophthalmic surgery, and hydrogel-based formulations of existing ophthalmic drugs. To get to early revenues, I-Therapeutix will debut with an ocular bandage designed to improve outcomes in corneal and retinal surgeries. But an enormous market lies ahead for the start-up: there's a need to improve the delivery of drugs for glaucoma, today, the largest ophthalmic drug market, affecting 70 million people worldwide, and constituting a US market worth $1.7 billion.

Glaucoma Start-Ups Reach Critical Mass

Having validated high intraocular pressure as a certain target for intervention, the Ocular Hypertension Treatment Study spurred on a new wave of innovation in medical devices for glaucoma. Numerous start-ups formed five or six years ago are now beginning to run their devices through clinical trials. Indeed, the field seems to have gained a critical mass of attention. Start-Up has identified more than a dozen emerging device companies treating glaucoma, and the disease remains a target for development programs and acquisitions on the pharmaceutical side as well.

Biomaterials Start-Ups

A broadly enabling technology can be almost a problem for a biomaterials start-up. The challenge is finding and exploiting the killer application.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090144

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel